(ARDX) Ardelyx - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.373m USD | Total Return: 56.5% in 12m
Avg Turnover: 16.6M
Qual. Beats: 0
Rev. Trend: 95.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -1.3 is critical
Altman Z'' -2.93 < 1.0 - financial distress zone
Fakeout Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Ardelyx, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted therapies for gastrointestinal and renal diseases. Its primary product portfolio includes IBSRELA, a treatment for irritable bowel syndrome with constipation, and XPHOZAH, designed to manage serum phosphorus levels in patients with chronic kidney disease on dialysis.
The company operates within the biotechnology sector, where business models often rely on high research and development expenditures to secure regulatory approvals for proprietary small molecule therapies. Unlike diversified pharmaceutical firms, specialized biotech companies frequently concentrate on niche therapeutic areas to address significant unmet medical needs in chronic disease management.
For a deeper look into the companys valuation metrics and financial health, consider exploring the data available on ValueRay.
- IBSRELA prescription growth and market share expansion in the IBS-C segment
- Medicare reimbursement coverage and patient access for XPHOZAH in dialysis care
- Quarterly revenue trajectory and path toward sustainable enterprise profitability
- Regulatory developments and legislative changes affecting phosphate binder pricing models
- Strategic partnerships and international licensing agreements for portfolio commercialization
| Net Income: -58.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 1.68 > 1.0 |
| NWC/Revenue: 63.67% < 20% (prev 65.48%; Δ -1.81% < -1%) |
| CFO/TA -0.07 > 3% & CFO -36.3m > Net Income -58.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (245.9m) vs 12m ago 3.03% < -2% |
| Gross Margin: 91.93% > 18% (prev 84.27%; Δ 7.66% > 0.5%) |
| Asset Turnover: 93.51% > 50% (prev 88.18%; Δ 5.33% > 0%) |
| Interest Coverage Ratio: -1.29 > 6 (EBIT TTM -37.4m / Interest Expense TTM 29.1m) |
| A: 0.54 (Total Current Assets 381.9m - Total Current Liabilities 109.6m) / Total Assets 504.5m |
| B: -1.95 (Retained Earnings -984.5m / Total Assets 504.5m) |
| C: -0.08 (EBIT TTM -37.4m / Avg Total Assets 457.4m) |
| D: 0.42 (Book Value of Equity 148.6m / Total Liabilities 355.9m) |
| Altman-Z'' = -2.93 = D |
| DSRI: 1.51 (Receivables 82.8m/46.5m, Revenue 427.7m/361.7m) |
| GMI: 0.92 (GM 84.27% / 91.93%) |
| AQI: 1.03 (AQ_t 0.23 / AQ_t-1 0.22) |
| SGI: 1.18 (Revenue 427.7m / 361.7m) |
| TATA: -0.04 (NI -58.1m - CFO -36.3m) / TA 504.5m) |
| Beneish M = -2.54 (Cap -4..+1) = A |
As of June 12, 2026, the stock is trading at USD 5.79 with a total of 3,633,004 shares traded.
Over the past week, the price has changed by +7.22%,
over one month by -12.41%,
over three months by -3.34% and
over the past year by +56.49%.
Ardelyx has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy ARDX.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.3 | 182% |
P/E Forward = 40.6504
P/S = 3.2115
P/B = 8.9755
P/EG = -0.08
Revenue TTM = 427.7m USD
EBIT TTM = -37.4m USD
EBITDA TTM = -34.0m USD
Long Term Debt = 203.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.51m USD (from shortTermDebt, last quarter)
Debt = 213.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.75m
Net Debt = -25.1m USD (calculated: Debt 213.0m - CCE 238.1m)
Enterprise Value = 1.35b USD (1.37b + Debt 213.0m - CCE 238.1m)
Interest Coverage Ratio = -1.29 (Ebit TTM -37.4m / Interest Expense TTM 29.1m)
EV/FCF = -275.6x (Enterprise Value 1.35b / FCF TTM -4.89m)
FCF Yield = -0.36% (FCF TTM -4.89m / Enterprise Value 1.35b)
FCF Margin = -1.14% (FCF TTM -4.89m / Revenue TTM 427.7m)
Net Margin = -13.58% (Net Income TTM -58.1m / Revenue TTM 427.7m)
Gross Margin = 91.93% ((Revenue TTM 427.7m - Cost of Revenue TTM 34.5m) / Revenue TTM)
Gross Margin QoQ = 94.91% (prev 90.60%)
Tobins Q-Ratio = 2.67 (Enterprise Value 1.35b / Total Assets 504.5m)
Interest Expense / Debt = 13.64% (Interest Expense 29.1m / Debt 213.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -29.6m (EBIT -37.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.77 (Total Current Assets 381.9m / Total Current Liabilities 137.8m)
Debt / Equity = 1.43 (Debt 213.0m / totalStockholderEquity, last quarter 148.6m)
Debt / EBITDA = 0.74 (negative EBITDA) (Net Debt -25.1m / EBITDA -34.0m)
Debt / FCF = 5.12 (negative FCF - burning cash) (Net Debt -25.1m / FCF TTM -4.89m)
Total Stockholder Equity = 152.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.69% (Net Income -58.1m / Total Assets 504.5m)
RoE = -38.11% (Net Income TTM -58.1m / Total Stockholder Equity 152.3m)
RoCE = -10.52% (EBIT -37.4m / Capital Employed (Equity 152.3m + L.T.Debt 203.5m))
RoIC = -7.88% (negative operating profit) (NOPAT -29.6m / Invested Capital 375.1m)
WACC = 7.91% (E(1.37b)/V(1.59b) * Re(7.46%) + D(213.0m)/V(1.59b) * Rd(13.64%) * (1-Tc(0.21)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 5.20%
[DCF] Fair Price = unknown (Cash Flow -4.89m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: 95.58 | Revenue CAGR: 81.26% | SUE: 0.31 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=-50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=-16.80% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.05 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+81.6% | GrowthRev=+33.9%
EPS next Year (2027-12-31): EPS=0.52 | Chg30d=-1.28% | Revisions=+43% | GrowthEPS=+1176.9% | GrowthRev=+35.2%
[Analyst] Revisions Ratio: -50%